Evgen Pharma PLC Upcoming conferences
13 Novembre 2023 - 8:00AM
RNS Non-Regulatory
TIDMEVG
Evgen Pharma PLC
13 November 2023
Evgen Pharma plc
("Evgen" or the "Company")
Attendance at upcoming investor conferences
Alderley Park, UK - 13 November 2023 : Evgen Pharma plc (AIM:
EVG), a clinical stage drug development
company developing sulforaphane-based medicines for the
treatment of cancer and other indications, notes that members of
its executive team will be participating in the following investor
events:
-- LSX InvEUR$stival Showcase , Monday 13 November 2023, London
Huw Jones (CEO) and Helen Kuhlman (CBO) will be attending, and
Huw Jones will be presenting on Stage 4: Biotech Public Stage at
13:45
-- Jefferies London Healthcare Conference, 14-16 November 2023, London
Huw Jones (CEO) and Helen Kuhlman (CBO) will be attending
-- Members of the Evgen Pharma executive team will be attending
the JP Morgan Healthcare Conference and Biotech Showcase on 8-11
January 2024 in San Francisco
If you would like to meet the team at any of these events,
please contact the Company via email at enquiries@evgen.com .
Please refer to the conference websites for further information
and up to date schedules.
-Ends-
Enquiries:
Evgen Pharma plc
Dr Huw Jones, CEO
Toni Hänninen, CFO
Dr Helen Kuhlman, CBO +44 1625 466591
Cavendish (Nominated Advisor
and Broker)
Geoff Nash / Teddy Whiley (Corporate
Finance)
Nigel Birks (ECM) +44 20 7220 0500
Instinctif Partners +44 207 457 2020
Melanie Toyne-Sewell / Rozi Morris evgen@instinctif.com
/ Jack Kincade
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company
developing sulforaphane based medicines for the treatment of
multiple diseases. The Company's core technology is Sulforadex(R),
a method for synthesising and stabilising the highly biologically
active compound sulforaphane and novel proprietary analogues based
on sulforaphane.
The Company's lead asset, SFX-01, is a patented composition of
synthetic sulforaphane and alpha-cyclodextrin and has undergone
clinical trials for oestrogen-positive (ER+) metastatic breast
cancer and recently a Phase 1b study of the Company's new enteric
coated tablet formulation. The FDA has granted Orphan Drug status
to SFX-01 in malignant glioma. SFX-01 will be investigated
initially in this indication as an investigator sponsored study in
the Netherlands.
The Company also has a wide number of collaborations with
leading academic centres in the UK, Europe and the US as part of
the continuing strategy to build the scientific data for the
compound. Recently, Evgen completed an out-licensing transaction
with Stalicla SA, a Swiss specialist company in neurodevelopmental
disorders, commencing with autism spectrum disorder. The deal, if
successful, will generate milestone payments of $160.5m and a
double-digit royalty on sales.
The Company has its headquarters and registered office at
Alderley Park, Cheshire. It is listed on AIM in London and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com .
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRABUBDBRUBDGXD
(END) Dow Jones Newswires
November 13, 2023 02:00 ET (07:00 GMT)
Evgen Pharma (LSE:EVG)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Evgen Pharma (LSE:EVG)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024